Revance Therapeutics (RVNC) 13.85 $RVNC Revance
Post# of 273257
Posted On: 09/03/2016 7:19:45 AM
Revance Therapeutics (RVNC) 13.85 $RVNC
Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference
BusinessWire - Tue Aug 30, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells Fargo Securities Healthcare Conference in Boston, MA.
RVNC: 13.85 (-0.19), WFC: 50.55 (+0.12)
Revance Releases Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:05PM CDT
--- Updates 2016 Financial Outlook -
RVNC: 13.85 (-0.19)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.96 (unch), MPAA: 29.06 (+0.39), NAV: 14.07 (+0.54), RVNC: 13.85 (-0.19), WFC: 50.55 (+0.12), SYF: 27.80 (+0.04), MSB: 9.57 (-0.06)
Why is Revance Therapeutics (RVNC) Stock Plummeting Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 10:48AM CDT
On Tuesday, shares of Revance Therapeutics Inc. (RVNC) are plummeting, down over 22% in morning trading after the company reported disappointing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.85 (-0.19)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), RVNC: 13.85 (-0.19), BMY: 56.35 (-0.41)
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
GlobeNewswire - Mon Jun 13, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.85 (-0.19)
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
GlobeNewswire - Thu Jun 02, 5:12PM CDT
- Portfolio covers diverse and novel indications, compositions and formulations -
RVNC: 13.85 (-0.19)
Revance to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.
RVNC: 13.85 (-0.19)
Revance reports 1Q loss
Automated Insights - Mon May 09, 5:48PM CDT
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $19.9 million in its first quarter.
RVNC: 13.85 (-0.19)
Revance Releases First Quarter 2016 Results
GlobeNewswire - Mon May 09, 3:06PM CDT
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -
RVNC: 13.85 (-0.19)
Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
GlobeNewswire - Mon Apr 25, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.
RVNC: 13.85 (-0.19)
Axillary Hyperhidrosis Pipeline Review H2 2015
M2 - Tue Feb 02, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/w8hlmc/axillary) has announced the addition of the "Axillary Hyperhidrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Axillary Hyperhidrosis Overview - Therapeutics Development - Pipeline Products for Axillary Hyperhidrosis - Overview - Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis - Axillary Hyperhidrosis - Therapeutics under Development by Companies - Axillary Hyperhidrosis - Therapeutics under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Axillary Hyperhidrosis - Products under Development by Companies - Axillary Hyperhidrosis - Products under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Companies Involved in Therapeutics Development - Allergan Plc - Brickell Biotech, Inc. - Dermira Inc. - GlaxoSmithKline Plc - Revance Therapeutics, Inc. - TheraVida, Inc For more information visit http://www.researchandmarkets.com/research/w8hlmc/axillary
AGN: 235.96 (-1.80), DERM: 32.52 (+0.30), RVNC: 13.85 (-0.19), GSK: 44.26 (+1.28)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.43 (-0.02), TRVN: 6.75 (-0.02), VRTX: 95.11 (+0.36), RDHL: 15.11 (+0.23), ZSAN: 0.81 (+0.04), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), ACOR: 24.27 (-0.07), NKTR: 18.45 (+0.34), AGN: 235.96 (-1.80), CORI: 5.75 (-0.05), ALDR: 31.52 (-1.02), CLCD: 10.66 (+0.41), MRK: 62.98 (+0.08), TEVA: 51.22 (+0.32), RVNC: 13.85 (-0.19), POZN: 5.94 (-0.43)
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:30AM CST
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), RVNC: 13.85 (-0.19), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19)
5 Biotech Stocks That Doubled in 2015
Arpita Dutt - Zacks Investment Research - Thu Jan 07, 11:17AM CST
Here is a look at 5 biotech stocks that doubled in 2015 despite the volatility in the sector.
HRTX: 17.70 (-0.63), SRPT: 26.89 (+0.33), LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), RVNC: 13.85 (-0.19), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19)
Dystonia therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/kz7qhs/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dystonia Overview - Therapeutics Development - Pipeline Products for Dystonia - Overview - Pipeline Products for Dystonia - Comparative Analysis - Dystonia - Therapeutics under Development by Companies - Dystonia - Therapeutics under Investigation by Universities/Institutes - Dystonia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dystonia - Products under Development by Companies - Dystonia - Products under Investigation by Universities/Institutes - Dystonia - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Advicenne Pharma - EpiVax, Inc. - Ipsen S.A. - Revance Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kz7qhs/dystonia
RVNC: 13.85 (-0.19)
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
GlobeNewswire - Wed Dec 23, 3:05PM CST
Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced interim efficacy and safety results from its Phase 2 trial of its RT001 topical botulinum toxin type A investigational drug product candidate for the treatment of axillary hyperhidrosis (excessive underarm sweating). The trial was designed to evaluate safety and efficacy of two doses of RT001 applied on a single day of treatment. Although the trial sample size was not chosen to meet statistical significance, using quantitative gravimetric measurements, the data was positive and showed that a single treatment of RT001 topical gel achieved clinically meaningful efficacy at Week 4. Using the qualitative Hyperhidrosis Disease Severity Scale (HDSS), RT001 showed a strong efficacy trend for both 1-point and 2-point improvement. Both doses of RT001 appear to be safe and well tolerated.
RVNC: 13.85 (-0.19)
Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference
BusinessWire - Tue Aug 30, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells Fargo Securities Healthcare Conference in Boston, MA.
RVNC: 13.85 (-0.19), WFC: 50.55 (+0.12)
Revance Releases Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:05PM CDT
--- Updates 2016 Financial Outlook -
RVNC: 13.85 (-0.19)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.96 (unch), MPAA: 29.06 (+0.39), NAV: 14.07 (+0.54), RVNC: 13.85 (-0.19), WFC: 50.55 (+0.12), SYF: 27.80 (+0.04), MSB: 9.57 (-0.06)
Why is Revance Therapeutics (RVNC) Stock Plummeting Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 10:48AM CDT
On Tuesday, shares of Revance Therapeutics Inc. (RVNC) are plummeting, down over 22% in morning trading after the company reported disappointing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.85 (-0.19)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), RVNC: 13.85 (-0.19), BMY: 56.35 (-0.41)
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
GlobeNewswire - Mon Jun 13, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.85 (-0.19)
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
GlobeNewswire - Thu Jun 02, 5:12PM CDT
- Portfolio covers diverse and novel indications, compositions and formulations -
RVNC: 13.85 (-0.19)
Revance to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.
RVNC: 13.85 (-0.19)
Revance reports 1Q loss
Automated Insights - Mon May 09, 5:48PM CDT
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $19.9 million in its first quarter.
RVNC: 13.85 (-0.19)
Revance Releases First Quarter 2016 Results
GlobeNewswire - Mon May 09, 3:06PM CDT
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -
RVNC: 13.85 (-0.19)
Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
GlobeNewswire - Mon Apr 25, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.
RVNC: 13.85 (-0.19)
Axillary Hyperhidrosis Pipeline Review H2 2015
M2 - Tue Feb 02, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/w8hlmc/axillary) has announced the addition of the "Axillary Hyperhidrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Axillary Hyperhidrosis Overview - Therapeutics Development - Pipeline Products for Axillary Hyperhidrosis - Overview - Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis - Axillary Hyperhidrosis - Therapeutics under Development by Companies - Axillary Hyperhidrosis - Therapeutics under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Axillary Hyperhidrosis - Products under Development by Companies - Axillary Hyperhidrosis - Products under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Companies Involved in Therapeutics Development - Allergan Plc - Brickell Biotech, Inc. - Dermira Inc. - GlaxoSmithKline Plc - Revance Therapeutics, Inc. - TheraVida, Inc For more information visit http://www.researchandmarkets.com/research/w8hlmc/axillary
AGN: 235.96 (-1.80), DERM: 32.52 (+0.30), RVNC: 13.85 (-0.19), GSK: 44.26 (+1.28)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.43 (-0.02), TRVN: 6.75 (-0.02), VRTX: 95.11 (+0.36), RDHL: 15.11 (+0.23), ZSAN: 0.81 (+0.04), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), ACOR: 24.27 (-0.07), NKTR: 18.45 (+0.34), AGN: 235.96 (-1.80), CORI: 5.75 (-0.05), ALDR: 31.52 (-1.02), CLCD: 10.66 (+0.41), MRK: 62.98 (+0.08), TEVA: 51.22 (+0.32), RVNC: 13.85 (-0.19), POZN: 5.94 (-0.43)
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:30AM CST
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), RVNC: 13.85 (-0.19), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19)
5 Biotech Stocks That Doubled in 2015
Arpita Dutt - Zacks Investment Research - Thu Jan 07, 11:17AM CST
Here is a look at 5 biotech stocks that doubled in 2015 despite the volatility in the sector.
HRTX: 17.70 (-0.63), SRPT: 26.89 (+0.33), LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), RVNC: 13.85 (-0.19), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19)
Dystonia therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/kz7qhs/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dystonia Overview - Therapeutics Development - Pipeline Products for Dystonia - Overview - Pipeline Products for Dystonia - Comparative Analysis - Dystonia - Therapeutics under Development by Companies - Dystonia - Therapeutics under Investigation by Universities/Institutes - Dystonia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dystonia - Products under Development by Companies - Dystonia - Products under Investigation by Universities/Institutes - Dystonia - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Advicenne Pharma - EpiVax, Inc. - Ipsen S.A. - Revance Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kz7qhs/dystonia
RVNC: 13.85 (-0.19)
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
GlobeNewswire - Wed Dec 23, 3:05PM CST
Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced interim efficacy and safety results from its Phase 2 trial of its RT001 topical botulinum toxin type A investigational drug product candidate for the treatment of axillary hyperhidrosis (excessive underarm sweating). The trial was designed to evaluate safety and efficacy of two doses of RT001 applied on a single day of treatment. Although the trial sample size was not chosen to meet statistical significance, using quantitative gravimetric measurements, the data was positive and showed that a single treatment of RT001 topical gel achieved clinically meaningful efficacy at Week 4. Using the qualitative Hyperhidrosis Disease Severity Scale (HDSS), RT001 showed a strong efficacy trend for both 1-point and 2-point improvement. Both doses of RT001 appear to be safe and well tolerated.
RVNC: 13.85 (-0.19)
(0)
(0)Scroll down for more posts ▼